Chongqing Fochon Pharmaceuticals Co. Ltd. has divulged apoptosis regulator Bcl-2 inhibitors reported to be useful for the treatment of cancer, Addison’s disease, allergy, asthma, atherosclerosis, ankylosing spondylitis, Alzheimer’s disease and systemic lupus erythematosus, among others.
Researchers from Fochon Biosciences Ltd. have reported the discovery and preclinical evaluation of a novel second-generation B-cell lymphoma 2 (BCL2) inhibitor, FCN-683, being developed for the treatment of B-cell malignancies. FCN-683 showed the ability to potently and selectively inhibit both wild-type BCL2 (IC50=0.11 nM) and multiple clinically relevant venetoclax-resistant mutants, including G101V, D103E/V/Y, F104L, A113G, R129L and V156D.
Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. researchers have developed prodrugs acting as apoptosis regulator Bcl-2 inhibitors reported to be useful for the treatment of cancer, particularly chronic myeloid leukemia.
Researchers from Hangzhou Healzen Therapeutics Co. Ltd. and Biopolar Hongye (Nantong) Pharmaceutical Co. Ltd. presented the discovery and preclinical characterization of a next-generation Bcl-2 inhibitor, HZ-L105, being developed for the treatment of hematological cancers.
Innocare Pharma Ltd. has received IND approval from China's National Medical Products Administration (NMPA) to begin clinical trials of its B-cell lymphoma-2 (BCL2) inhibitor ICP-248.
Zentera Therapeutics Inc. completed a $75 million series B financing round to help further its candidates in China, as it paves the way for a listing in Hong Kong next year.
HONG KONG – New York and San Diego-based Zentalis Pharmaceuticals Inc. has gained $20 million in a series A financing round to support a Chinese joint venture called Zentera Therapeutics.
HONG KONG – New York and San Diego-based Zentalis Pharmaceuticals Inc. has gained $20 million in a series A financing round to support a Chinese joint venture called Zentera Therapeutics.
